chartexchange

Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire Inc. | Nov 3, 2026 7:00 AM EST

– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation –

Read original article